Tag: Blood disorder

Bristol Myers Squibb gets Reblozyl EC approval for anemia associated with NTD beta thalassemia

businessnewstoday- March 4, 2023

Bristol Myers Squibb (BMY) has secured full marketing authorization for Reblozyl (luspatercept) from the European Commission (EC) for treating anemia associated with non-transfusion-dependent (NTD) beta ... Read More

Novo Nordisk acquires SCD drug developer Forma Therapeutics

businessnewstoday- October 16, 2022

Novo Nordisk acquisition of Forma Therapeutics : Danish pharma company Novo Nordisk has closed the previously announced $1.1 billion acquisition of Forma Therapeutics, a clinical-stage ... Read More

Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn

pallavi123- August 8, 2022

Pfizer has agreed to acquire Global Blood Therapeutics (GBT), a publicly-listed American biopharma company, in a deal worth around $5.4 billion with an aim to ... Read More

Agios Pharmaceuticals gets PYRUKYND FDA approval for hemolytic anemia

pallavi123- February 20, 2022

Agios Pharmaceuticals has secured approval for PYRUKYND (mitapivat) from the US Food and Drug Administration (FDA) for the treatment of hemolytic anemia in adult patients ... Read More

Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia

pharmanewsdaily- November 9, 2019

Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) for the treatment ... Read More

Sickle cell disease drug developer Modus Therapeutics raises $16m in new funding

pharmanewsdaily- July 15, 2018

Modus Therapeutics, a Swedish biotech company focused on developing sickle cell disease drugs, has raised SEK 140 million ($15.76 million) in a funding round led ... Read More